Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cordlife Group ( (SG:P8A) ) just unveiled an announcement.
Cordlife Group has updated investors on the status of court claims brought by clients alleging damage to stored cord blood units, announcing that it has applied to the High Court to convert the existing Originating Application into an originating claim so the conversion request can be heard together with the substantive hearing. The board is continuing to assess the financial impact of these OA 1365 claims on its results for the financial year ending 31 December 2026 and has cautioned that an adverse court order requiring payment of the claims would negatively affect the Group’s FY2026 financial position, while advising shareholders and potential investors to exercise caution when trading its shares pending further developments.
The most recent analyst rating on (SG:P8A) stock is a Sell with a S$0.13 price target. To see the full list of analyst forecasts on Cordlife Group stock, see the SG:P8A Stock Forecast page.
More about Cordlife Group
Cordlife Group Limited is a Singapore-based healthcare company specialising in the storage of umbilical cord blood and related cellular products for clients, operating through a network of subsidiaries in Asia and focused on long-term preservation services for families seeking stem cell banking solutions.
Average Trading Volume: 37,920
Technical Sentiment Signal: Strong Sell
Current Market Cap: S$33.19M
See more data about P8A stock on TipRanks’ Stock Analysis page.